363 related articles for article (PubMed ID: 22261336)
1. mTOR inhibitors in cancer therapy.
Zaytseva YY; Valentino JD; Gulhati P; Evers BM
Cancer Lett; 2012 Jun; 319(1):1-7. PubMed ID: 22261336
[TBL] [Abstract][Full Text] [Related]
2. [mTOR complexes -- molecular spiders in molecular networks].
Kopper L; Tímár J
Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
[TBL] [Abstract][Full Text] [Related]
3. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
4. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
7. Targeting endocrine resistance: is there a role for mTOR inhibition?
Sheri A; Martin LA; Johnston S
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
[TBL] [Abstract][Full Text] [Related]
8. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
9. mTOR signaling, function, novel inhibitors, and therapeutic targets.
Watanabe R; Wei L; Huang J
J Nucl Med; 2011 Apr; 52(4):497-500. PubMed ID: 21421716
[TBL] [Abstract][Full Text] [Related]
10. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
11. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment.
LoRusso PM
Oncology; 2013; 84(1):43-56. PubMed ID: 23128843
[TBL] [Abstract][Full Text] [Related]
13. The promise of mTOR inhibitors in the treatment of colorectal cancer.
Kim DD; Eng C
Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors in the treatment of breast cancer.
Vinayak S; Carlson RW
Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
[TBL] [Abstract][Full Text] [Related]
15. Current treatment strategies for inhibiting mTOR in cancer.
Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
[TBL] [Abstract][Full Text] [Related]
16. Markers for efficacy of mammalian target of rapamycin inhibitor.
Liao YM; Sy A; Yen Y
Anticancer Res; 2012 Oct; 32(10):4235-44. PubMed ID: 23060543
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
18. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
19. An overview of the mTOR pathway as a target in cancer therapy.
Gentzler RD; Altman JK; Platanias LC
Expert Opin Ther Targets; 2012 May; 16(5):481-9. PubMed ID: 22494490
[TBL] [Abstract][Full Text] [Related]
20. [Use of mTOR-inhibitors in solid tumors].
Seidel C; Grünwald V
Med Monatsschr Pharm; 2011 Apr; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]